Ovid posted a net loss of $15 million, or $0.08 per share, for the quarter ended June 30, 2026.
Research and development expense rose to $10 million from $6.5 million a year earlier on higher OV329 and OV4071 activity.
General and administrative expense increased to $6.5 million from $4.9 million; total operating expenses climbed to $16.4 million from $11.3 million.
Cash position and pipeline update
Cash, cash equivalents and marketable securities totaled $169.8 million, with runway expected into 2029.
OV4071 advanced in Phase 1; OV329 began Phase 2 in treatment-resistant focal onset seizures, with photosensitivity results expected near year-end 2026.
OVID•
